Drug intelligence / Profile preview

Anti-HER2 ADC

Development stage: Preclinical
Lead developer: AlphaMab Oncology
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-HER2 ADC refers to a class of antibody-drug conjugates designed to target the Human Epidermal growth factor Receptor 2 (HER2) protein, which is overexpressed in certain cancers, particularly breast cancer. These drugs typically consist of an anti-HER2 monoclonal antibody linked to a cytotoxic payload. The antibody component specifically binds to HER2-expressing cancer cells, facilitating the internalization of the conjugate. Once inside the cell, the cytotoxic payload is released, leading to cell death. This targeted delivery mechanism aims to reduce systemic toxicity compared to traditional chemotherapy.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Anti-HER2 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-HER2 ADC.

Explore the full profile